Ryvu Therapeutics S.A. (WSE:RVU)
Poland · Delayed Price · Currency is PLN 15.38
-0.02 (-0.13%)
Jun 12, 2026, 5:00 PM CET
Ryvu Therapeutics Earnings Call Transcripts
Fiscal Year 2024
-
RVU120 is being evaluated in four Phase II studies for hematologic malignancies, showing early signs of efficacy and a favorable safety profile, especially in genetically defined AML and MDS cohorts. Enrollment and operational progress are strong, with key data readouts expected in the first half of 2025.